Skip to main content

FDA Panel to Meet About Epigenomics' PMA for Colorectal Cancer Test

NEW YORK (GenomeWeb News) – A US Food and Drug Administration panel is tentatively set to meet in four months to discuss Epigenomics’ colorectal cancer screening test, the company said today.

FDA’s Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is scheduled to meet on March 25, 2014 over Epigenomics’ premarket approval submission for its Epi proColon test. The company completed its submission in January, and in February, FDA granted Epigenomics’ application priority review status.

Earlier this month, the company announced flat revenues for its third quarter.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.